Processa Announces $200M Private Placement And Acquisition Of Vidya Therapeutics BTK Inhibitor VT-7208; Existing Shareholders To Own About 0.9% Fully Diluted

8-K filing — Processa Pharmaceuticals, Inc. (PCSA)

Filed: 2026-08-04 AccNo: 0001493152-26-036032 Size: 226 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits

Crude Oil Surges 7%; General Dynamics Posts Upbeat Earnings

Dow Jones falls 800+ pts; energy shares up 2.6%; General Dynamics beats earnings estimates; Verra Mobility reaches agreement with Avis.

Dow Tumbles 400 Points; Procter & Gamble Shares Fall After Q4 Results

US stocks mostly lower, Dow Jones falls 400+ pts. Energy shares up 3%. Procter & Gamble shares down 4% after worse-than-expected sales & EPS. Asian markets mixed.

Processa Pharmaceuticals shares are trading lower after the company announced a $200 million private placement and acquisition of Vidya Therapeutics BTK Inhibitor VT-7208.